DRDO’s anti-Covid oral drug 2DG commercially launched by Dr Reddy’s

June 29: Dr Reddy’s Laboratory on Monday announced the commercial launch of anti-Covid-19 oral drug 2DG developed by the Defence Research and Development Organisation (DRDO). The anti-Covid drug was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a laboratory of the DRDO, in collaboration with Dr Reddy’s. It is an oral drug.

The drug will be supplied to major government and private hospitals across India. The drug was approved for emergency use in May, 2021. The maximum selling price of each sachet has been capped at Rs 990 with a discounted rate offered to government institutions. The drug (2-DG) can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe Covid-19 patients as an adjunct therapy to the existing standard of care.